SCHEMBL1839616

SCHEMBL1839616

COc1ncnc2[nH]nc(-c3cccnc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.43
IDO1 P14902 1/20 0.43
PIM1 P11309 4/20 0.43
MAP2K4 P45985 1/20 0.43
CHEK1 O14757 2/20 0.42
AXL P30530 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
CYP2A6 P11509 1/20 0.40
PIK3CD O00329 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
HCK P08631 1/20 0.39
SRC P12931 1/20 0.39
KDR P35968 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1841197 0.83 LRRK2 (0.49) LRRK2
SCHEMBL13826001 0.81 PIK3CD (0.51) LRRK2IDO1PIM1MAP2K4AXL
SCHEMBL2243597 0.79 AURKA (0.46) LRRK2PIK3CDABL1EGFRPIK3CA
SCHEMBL1838247 0.76 LRRK2 (0.51) LRRK2PIM1GSK3B
SCHEMBL15805235 0.73 KIT (0.54) CHEK1ALDH1A1SMN1; SMN2
SCHEMBL15922429 0.73 MKNK1 (0.61) PIM1PIM3PIM2
SCHEMBL12347206 0.73 PIK3CD (0.48) LRRK2PIM1CHEK1AXLPIK3CD
Hydrochloric Acid SCHEMBL28019349 0.69 ALDH1A1 (0.40) ALDH1A1
SCHEMBL18292281 0.69 CHEK1 (0.48) LRRK2IDO1PIM1MAP2K4CHEK1
SCHEMBL10981820 0.69 MAP2K4 (0.52) LRRK2IDO1PIM1MAP2K4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 LRRK2 1532/4885IDO1 3775/4885PIM1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.